Springworks Therapeutics, Inc., based in the USA, is a pharmaceutical company with a focus on precision medicine for rare diseases and cancer. With a Risk Rating Score of 32.0, it is considered high risk in terms of ESG factors. The company is known for its innovative approach in developing small molecule targeted oncology products, with ongoing clinical trials for rare tumor types and genetically defined cancers.